Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Omnicell
  4. Financial Ratios
Omnicell logo
Omnicell OMCL
$ 37.35 -1.09%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Omnicell Financial Ratios 2025-2008 | OMCL

Brief overview of Omnicell's valuation and returns

This overview follows the five latest available observations from 2020 through 2025.

The latest available valuation ratios are P/E 676.48x (median 155.81x), EV/EBITDA 23.04x (median 33.52x), P/S 1.17x (median 1.6x). The combined multiple level is about 21.3% below the company's historical norm, suggesting more cautious expectations.

At the current P/E, inverse earnings yield is 0.1%, a useful bridge between price and business earnings.

End-period return metrics are ROE 0.2%, ROA 0.1%, ROCE 0.4%. Efficiency ratios are restrained, with capital and assets producing modest returns.

The cash conversion cycle is 98 days versus 102.5 days initially. Turnover changed little.

Conclusion

Omnicell's restrained price comes with modest current quality. Better efficiency is needed for revaluation.

Annual Financial Ratios Omnicell

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

P/E

 676.5 142.0 -58.3 447.4 83.8 155.8 56.9 65.5 89.9 2122.6 32.6 37.2 37.3 32.3 48.0 84.6 695.2 -

P/S

 1.2 1.6 1.0 2.0 5.8 5.6 3.9 3.1 2.6 1.8 2.1 2.6 2.4 1.7 2.0 1.9 1.4 -

EPS

 0.0 0.3 -0.5 0.1 1.8 0.8 1.5 1.0 0.8 0.3 0.9 0.9 0.7 0.5 0.3 0.1 0.0 -

EV (Enterprise Value)

 1.93 B 2.29 B 1.76 B 3.28 B 7.17 B 5.39 B 3.76 B 2.81 B 2.28 B 1.73 B 1.1 B 1.18 B 934 M 595 M 387 M 316 M 139 M -120 M

EBITDA per Share

 1.83 1.79 1.16 1.91 3.74 2.27 3.44 2.44 1.53 1.79 1.98 1.96 1.54 1.21 0.731 0.56 0.32 -

EV/EBITDA

 23.0 27.7 33.5 38.7 44.1 55.8 24.0 26.5 35.4 22.8 13.0 14.4 14.7 11.4 12.7 17.4 13.8 -

PEG

 102.17 -231.35 17.63 27.14 3.6 18.3 1.05 0.88 0.03 -21.65 19.07 1.51 0.91 0.56 0.45 - - -

P/B

 1.1 1.4 1.0 2.2 5.7 5.2 4.1 3.6 3.6 3.0 2.5 2.9 2.6 1.7 1.8 1.6 - -

P/CF

 10.9 9.5 6.6 32.5 28.2 27.0 41.9 49.9 -324.5 68.2 73.4 26.7 25.7 27.7 27.5 - - -

ROE %

 0.17 1.01 -1.71 0.50 6.79 3.33 7.26 5.55 3.98 0.14 7.64 7.82 6.87 5.26 3.67 1.84 0.18 -

ROA %

 0.10 0.59 -0.91 0.26 3.63 1.76 4.94 3.49 2.10 0.06 5.31 5.45 4.87 3.66 2.87 1.43 - -

ROCE %

 0.34 0.02 -1.88 -0.13 7.07 2.29 7.81 5.06 0.75 0.86 9.95 11.07 8.82 7.56 5.35 3.34 0.28 -

Current Ratio

 2.7 2.4 2.1 2.0 2.2 2.1 2.0 1.9 1.7 1.7 2.1 2.5 2.5 2.2 4.8 4.4 - -

DSO

 72.9 83.4 87.7 76.1 69.5 83.6 88.9 91.0 96.4 79.2 81.3 68.5 56.2 64.1 54.9 35.1 - -

DIO

 50.8 56.6 72.3 69.0 68.3 77.9 85.7 88.7 89.0 66.8 71.9 55.6 64.8 68.5 60.2 - - -

DPO

 25.7 27.6 30.4 34.8 35.3 33.0 36.8 33.5 44.7 26.1 34.9 34.3 33.9 46.5 36.6 23.1 - -

Operating Cycle

 123.7 140.0 160.1 145.1 137.8 161.4 174.5 179.7 185.5 146.0 153.2 124.1 121.0 132.5 115.1 - - -

Cash Conversion Cycle

 98.0 112.4 129.6 110.3 102.5 128.4 137.7 146.2 140.8 119.9 118.3 89.9 87.1 86.1 78.5 - - -

All numbers in USD currency

Quarterly Financial Ratios Omnicell

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

 0.24 0.53 0.25 -0.049999999999999996 0.12 0.12 -0.15 0.34 0.19 0.08 -0.34 -0.32 0.12 0.08 -0.33 -0.64 0.38 0.21 0.19 0.31000000000000005 0.67 0.47 0.33 0.39 0.21 -0.1 0.27 0.53 0.48 0.39 0.08 0.37 0.35 0.17 0.07 0.8300000000000001 0.21 0.02 -0.29 0.26 0.05 -0.03 -0.01 0.21999999999999997 0.22 0.24 0.18 0.26 0.2 0.22 0.18 0.18999999999999995 0.22 0.17 0.1 0.16999999999999998 0.21 0.04 0.07 0.12 0.09 0.08 0.02

EBITDA per Share

 0.42 0.81 0.47 -16.6 0.3 0.29 -0.12 179 0.26 0.19 -0.35 -167 0.25 0.35 -0.33 -318 0.61 0.48 0.32 107 0.82 0.81 0.6 -1.16 K 0.34 -0.06 0.39 151 0.7 0.57 0.43 110 0.59 0.34 0.17 103 0.49 0.16 -0.27 174 0.38 0.25 0.31 -109 0.44 0.39 0.32 0.92 0.41 0.38 0.31 51.3 0.34 0.3 0.16 -1.21 K 0.37 0.09 0.11 -708 0.15 0.13 0.09

ROE %

 3.46 3.07 1.63 0.17 1.61 1.86 1.73 0.97 -1.52 -1.75 -1.76 -1.76 -3.06 -2.05 -1.52 0.56 4.29 5.45 6.56 7.19 7.67 5.99 3.56 3.45 4.38 5.89 8.44 7.60 7.17 6.89 5.95 5.97 9.43 8.87 8.16 5.34 1.73 0.56 -0.14 2.12 1.91 3.50 5.97 7.62 8.17 8.04 7.91 8.05 7.64 7.88 7.62 6.98 6.82 6.99 5.66 5.42 5.08 3.83 4.30 3.73 1.08 0.95 0.24

ROA %

 2.22 1.96 1.01 0.11 0.96 1.06 0.96 0.60 -0.79 -0.92 -0.92 -0.90 -1.54 -1.02 -0.76 0.30 2.23 2.89 3.51 3.87 4.12 3.20 1.81 1.98 2.86 3.95 5.64 5.00 4.59 4.28 3.58 3.57 5.27 4.81 4.38 2.98 0.90 0.28 -0.05 1.04 1.37 2.55 4.13 5.28 5.60 5.54 5.54 5.65 5.38 5.58 5.41 4.93 4.80 4.91 3.97 3.86 3.75 2.94 3.34 2.90 0.84 0.74 0.18

ROCE %

 4.17 3.78 2.21 0.35 1.14 1.07 0.72 0.30 -1.77 -2.06 -1.80 -1.91 -2.80 -1.98 -1.70 0.02 3.08 3.78 4.82 5.62 6.01 4.98 2.51 2.52 3.42 5.16 7.77 7.86 7.81 7.47 6.45 5.21 5.05 4.66 3.67 1.27 1.16 0.13 0.22 2.80 3.45 5.83 8.53 10.52 10.99 11.06 11.27 11.40 11.16 10.67 10.22 8.96 8.94 9.57 7.86 7.91 7.20 5.55 6.27 5.47 1.61 1.46 0.36

Current Ratio

 2.8 2.8 2.7 2.7 2.7 2.4 2.4 2.4 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.1 2.0 2.0 2.1 2.2 2.2 2.1 2.1 2.1 3.6 3.5 3.1 2.9 2.8 2.6 2.7 2.4 2.3 2.2 2.2 2.0 2.0 1.9 1.9 1.9 1.8 1.8 3.3 3.1 3.0 3.5 3.3 3.2 3.4 3.5 3.4 3.4 3.4 3.4 3.3 3.4 3.5 4.5 4.5 4.5 4.5 4.5

DSO

 68.6 69.7 68.7 67.2 70.3 76.0 86.0 75.5 79.6 80.7 92.8 92.5 83.5 91.0 97.6 100.2 87.1 82.7 76.0 69.6 68.3 69.5 71.7 69.2 80.5 96.5 89.7 77.5 81.5 85.8 90.0 86.7 85.0 88.3 95.1 - 78.9 71.2 86.5 85.2 86.9 82.5 69.7 78.3 84.9 83.1 67.1 66.8 72.0 68.7 60.1 52.9 62.0 63.1 63.3 54.8 53.8 51.7 55.2 61.4 63.1 61.1 -

DIO

 52.3 56.1 53.9 51.8 55.2 55.2 51.7 50.8 53.6 55.3 63.5 67.3 67.5 75.3 79.5 76.4 71.8 75.7 69.5 63.2 62.6 66.0 67.8 72.5 84.8 89.0 83.9 78.2 82.0 83.6 88.6 83.3 87.9 93.9 90.2 83.5 77.8 81.3 90.4 67.0 70.8 70.0 59.4 67.2 70.8 65.3 54.2 50.1 54.6 58.2 60.3 57.7 62.0 54.0 58.0 59.6 61.5 53.4 56.4 59.3 52.4 59.5 -

DPO

 29.7 31.0 27.5 26.4 32.4 32.4 30.2 27.5 27.8 26.1 26.2 28.2 26.6 30.7 34.9 35.5 34.3 36.9 38.7 41.2 39.9 35.8 32.1 28.2 28.0 31.9 35.4 34.7 34.7 31.6 33.1 31.8 31.9 33.4 39.2 44.1 46.8 40.7 34.6 29.8 35.5 33.4 27.4 33.1 37.6 39.5 34.5 33.7 36.3 36.4 35.4 38.2 45.8 36.9 40.0 41.3 41.0 33.3 34.7 42.9 43.8 42.6 -

Operating Cycle

 121.0 125.8 122.6 119.0 125.5 131.2 137.6 126.3 133.3 136.0 156.2 159.7 151.0 166.3 177.1 176.6 159.0 158.4 145.5 132.9 130.9 135.5 139.5 141.7 165.3 185.4 173.6 155.7 163.5 169.4 178.7 170.0 172.9 182.2 185.3 83.5 156.7 152.5 177.0 152.2 157.7 152.5 129.1 145.5 155.7 148.4 121.2 116.9 126.6 126.8 120.4 110.6 124.0 117.1 121.2 114.4 115.3 105.1 111.6 120.7 115.5 120.7 -

Cash Conversion Cycle

 91.3 94.8 95.0 92.5 93.2 98.8 107.4 98.8 105.5 109.9 130.1 131.5 124.4 135.6 142.2 141.1 124.7 121.6 106.8 91.6 91.0 99.8 107.4 113.5 137.3 153.5 138.2 121.0 128.9 137.8 145.6 138.2 141.1 148.8 146.1 39.4 109.9 111.8 142.3 122.4 122.2 119.1 101.6 112.4 118.0 108.9 86.8 83.2 90.3 90.4 85.0 72.4 78.2 80.2 81.2 73.1 74.4 71.8 76.9 77.8 71.7 78.1 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Omnicell, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Health information services industry

Issuer Price % 24h Market Cap Country
Signify Health Signify Health
SGFY
 		- -0.02 % $ 7.21 B usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
 		- - $ 255 M usaUSA
Change Healthcare Change Healthcare
CHNG
 		- - $ 9.03 B usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
 		$ 8.65 -0.17 % $ 161 M usaUSA
Cerner Corporation Cerner Corporation
CERN
 		- - $ 27.9 B usaUSA
So-Young International So-Young International
SY
 		$ 2.07 -1.2 % $ 161 M chinaChina
Veeva Systems Veeva Systems
VEEV
 		$ 303.83 -2.03 % $ 49.7 B usaUSA
SCWorx Corp. SCWorx Corp.
WORX
 		$ 7.25 31.34 % $ 52.7 M usaUSA
Zhongchao Zhongchao
ZCMD
 		$ 0.96 -0.08 % $ 3.28 M chinaChina
HealthStream HealthStream
HSTM
 		$ 28.84 -1.76 % $ 866 M usaUSA
Accolade Accolade
ACCD
 		- 0.29 % $ 206 M usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
 		- -10.39 % $ 886 M usaUSA
NantHealth NantHealth
NH
 		- -46.64 % $ 10.4 M usaUSA
Covetrus Covetrus
CVET
 		- - $ 2.94 B usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
 		- - $ 1.6 B usaUSA
1Life Healthcare 1Life Healthcare
ONEM
 		- - $ 3.37 B usaUSA
iCAD iCAD
ICAD
 		- - $ 102 M usaUSA
R1 RCM R1 RCM
RCM
 		- - $ 3.81 B usaUSA
10x Genomics 10x Genomics
TXG
 		$ 58.86 1.38 % $ 7.34 B usaUSA
American Well Corporation American Well Corporation
AMWL
 		$ 11.95 -1.24 % $ 192 M usaUSA
Evolent Health Evolent Health
EVH
 		$ 4.58 0.77 % $ 523 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
 		$ 3.52 0.86 % $ 1.25 B usaUSA
Castlight Health, Inc. Castlight Health, Inc.
CSLT
 		- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
 		- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
 		- - $ 6.37 B usaUSA
Health Catalyst Health Catalyst
HCAT
 		$ 1.47 -2.0 % $ 103 M usaUSA
HealthEquity HealthEquity
HQY
 		$ 103.6 0.13 % $ 8.92 B usaUSA
Progyny Progyny
PGNY
 		$ 34.88 1.48 % $ 2.97 B usaUSA
Schrödinger Schrödinger
SDGR
 		$ 29.8 3.58 % $ 2.19 B usaUSA
Teladoc Health Teladoc Health
TDOC
 		$ 8.85 -6.2 % $ 1.56 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
 		- 4.4 % $ 133 M usaUSA
Phreesia Phreesia
PHR
 		$ 12.62 -0.71 % $ 754 M usaUSA
Akerna Corp. Akerna Corp.
KERN
 		- - $ 161 M usaUSA
MTBC MTBC
MTBC
 		- -0.58 % $ 51.7 M usaUSA
Premier Premier
PINC
 		- - $ 2.33 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
 		- - $ 21.4 M usaUSA